Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

- Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 -


- Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs...

Related Keywords

San Diego ,California ,United States ,New York ,Clayb Siegall , ,Nasdaq ,Immunome Inc ,Twitter ,Linkedin ,Pharmaceuticals Inc ,Zentalis Pharmaceuticals Inc ,Exchange Commission ,Chief Executive Officer ,Cam Gallagher ,Zentalis Pharmaceuticals ,Exchange Act ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Markets ,